arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Taysha Gene Therapies, Inc.

TSHA
$4.92 ▼ -0.24 (-4.65%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

Taysha Gene Therapies, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -8.6%
FCF / Share $-0.11
Trailing P/E
Price / Book 4.1x
FCF Yield
Debt / Equity 0.13
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-46.64M
↓ -73.5%
Operating Margin Operating profit as % of sales
-450.8%
↓ -31.7%
FCF / Share Free cash flow per share
$-0.11
↑ +1.8%
Long-Term Debt Long-term obligations
$49.26M
↑ +0.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
18
Financial Health
48
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 28 quarters